Meda AB Receives Marketing Authorization for Zyclara in European Union

Meda AB announced that the European Commission (EC) has granted marketing authorization for Zyclara in the European Union (EU). Zyclara (imiquimod 3.75% cream) is a patented product for the treatment of actinic keratosis (AK). The approval is valid in all EU countries. Zyclara is treatment option which can detect and eliminate subclinical as well as clinical AK lesions on areas of the skin. Zyclara has shown in a clinical development program to be an effective therapy in eliminating both kinds of AK lesions and with low recurrence rate.